Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Cipla
Fuji
AstraZeneca
Colorcon
Citi

Generated: May 19, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,878,717

« Back to Dashboard

Which drugs does patent 6,878,717 protect, and when does it expire?

Patent 6,878,717 protects INTELENCE and is included in one NDA.

Protection for INTELENCE has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-eight patent family members in thirty-five countries.

Summary for Patent: 6,878,717
Title: HIV replication inhibiting pyrimidines
Abstract:This invention concerns the use of compounds of formula: ##STR1## the N-oxides, the pharmaceutically acceptable addition salts, quaternary amines and the stereochemically isomeric forms thereof, wherein -a.sup.1 =-a.sup.2 -a.sup.3 =a.sup.4 - forms a phenyl, pyridinyl, pyrimidinyl, pyridazinyl or pyrazinyl with the attached vinyl group; n is 0 to 4; and where possible 5; R.sup.1 is hydrogen, aryl, formyl, C.sub.1-6 alkylcarbonyl, C.sub.1-6 alkyl, C.sub.1-6 alkyloxy-carbonyl, substituted C.sub.1-6 alkyl, or substituted C.sub.1-6 alkyloxyC.sub.1-6 alkylcarbonyl; each R.sup.2 independently is hydroxy, halo, optionally substituted C.sub.1-6 alkyl, C.sub.2-6 alkenyl or C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.1-6 alkyloxy, C.sub.1-6 alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C.sub.1-6 alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalo-methylthio, --S(.dbd.O).sub.p R.sup.6, --NH--S(.dbd.O).sub.p R.sup.6, --C(.dbd.O)R.sup.6, --NHC(.dbd.O)H, --C(.dbd.O)NHNH.sub.2, --NHC(.dbd.O)R.sup.6, --C(.dbd.NH)R.sup.6 or a 5-membered heterocyclic ring; p is 1 or 2; L is optionally substituted C.sub.1-10 alkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl or C.sub.3-7 cycloalkyl; or L is --X--R.sup.3 wherein R.sup.3 is optionally substituted phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl; X is --NR.sup.1 --, --NH--NH--, --N.dbd.N--, --O--, --C(.dbd.O)--, --CHOH--, --S--, --S(.dbd.O)-- or --S(.dbd.O).sub.2 --; Q is hydrogen, C.sub.1-6 alkyl, halo, polyhalo-C.sub.1-6 alkyl or an optionally substituted amino group; Y represents hydroxy, halo, C.sub.3-7 cycloalkyl, optionally substituted C.sub.1-6 alkyl, C.sub.2-6 alkenyl or C.sub.2-6 alkynyl, C.sub.1-6 alkyloxy, C.sub.1-6 alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C.sub.1-6 alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, --S(.dbd.O).sub.p R.sup.6, --NH--S(.dbd.O).sub.p R.sup.6, --C(.dbd.O)R.sup.6, --NHC(.dbd.O)H, --C(.dbd.O)NHNH.sub.2, --NHC(.dbd.O)R.sup.6, --C(.dbd.NH)R.sup.6 or aryl; aryl is optionally substituted phenyl; Het is an optionally substituted heterocyclic radical; for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection.
Inventor(s): De Corte; Bart (Southampton, PA), De Jonge; Marc Rene (5045 CA Tilburg, NL), Heeres; Jan (Vosselaar, BE), Ho; Chih Yung (Lansdale, PA), Janssen; Paul Adriaan Jan (B2350 Vosselaar, BE), Kavash; Robert W. (Maple Glen, PA), Koymans; Lucien Maria Henricus (B-2300 Turnhout, BE), Kukla; Michael Joseph (Maple Glen, PA), Ludovici; Donald William (Quakertown, PA), Van Aken; Koen Jeanne Alfons (B-2300 Turnhout, BE)
Assignee:
Application Number:09/430,966
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 6,878,717
Patent Claim Types:
see list of patent claims
Use; Compound;

Drugs Protected by US Patent 6,878,717

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Janssen R And D INTELENCE etravirine TABLET;ORAL 022187-003 Mar 26, 2012 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Janssen R And D INTELENCE etravirine TABLET;ORAL 022187-001 Jan 18, 2008 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Janssen R And D INTELENCE etravirine TABLET;ORAL 022187-002 Dec 22, 2010 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,878,717

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
PCT/EP 99/07417Sep 24, 1999

International Family Members for US Patent 6,878,717

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 1683 ➤ Try a Free Trial
Argentina 024227 ➤ Try a Free Trial
Austria 233740 ➤ Try a Free Trial
Austria 455107 ➤ Try a Free Trial
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Medtronic
Cantor Fitzgerald
Teva
Farmers Insurance
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.